We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
Read MoreHide Full Article
Key Takeaways
Globus Medical faces inflation, geopolitical and rate uncertainty that can disrupt supply chains.
Globus Medical saw SG&A rise and incurred restructuring costs tied to integration efforts.
Globus Medical posted a $2.1M FX loss despite strong international sales growth in Q1 2026.
Globus Medical (GMED - Free Report) operates in a challenging environment caused by interest rate uncertainty, inflation and geopolitical tensions, which can disrupt supply chains and increase costs. While gross margin improved to 69.2% in the first quarter of 2026, it remains below management’s long-term target of the mid-70% range, leaving limited room to absorb higher costs.
Selling, general and administrative expenses rose to $297.8 million from $242.8 million a year earlier, mainly due to higher compensation and benefit costs associated with increased sales volume. The company also incurred restructuring expenses as it continues integration and synergy initiatives, which could lead to fluctuations in near-term operating costs.
Globus Medical’s international business adds another source of uncertainty. International net sales reached $155.0 million in the first quarter of 2026, increasing 35.6% year over year on a reported basis and 27.8% on a constant currency basis, highlighting the impact of exchange rate movements on reported results.
The company recorded a $2.1 million foreign currency transaction loss during the quarter, which reduced other income. With significant operations in regions such as Japan, the Eurozone, the United Kingdom and Australia, ongoing currency fluctuations could continue to affect revenue growth, profit margins and operating expenses over time.
Peer Update
Medtronic’s (MDT - Free Report) operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. It also embedded a roughly 1-point EPS drag from higher fuel and transportation costs tied to the recent shift in the geopolitical environment.
Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.
Edwards Lifesciences’ (EW - Free Report) extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The business is also currently experiencing staffing shortages within the hospital systems.
In the first quarter of 2026, these issues resulted in a 20.2% increase in COGS and a year-over-year decline of 64 basis points in gross margin. Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States. Foreign exchange rates negatively impacted the second quarter gross profit margin by 60 basis points compared to the prior year.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 37.1%, outperforming the industry’s 4.6% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month price-to-sales (P/S) of 3.26X compared with the industry median of 4.49X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
View the Zacks #1 Rank List
Image: Bigstock
Here's How Macro Trends and Currency Headwind Restrict GMED's Growth
Key Takeaways
Globus Medical (GMED - Free Report) operates in a challenging environment caused by interest rate uncertainty, inflation and geopolitical tensions, which can disrupt supply chains and increase costs. While gross margin improved to 69.2% in the first quarter of 2026, it remains below management’s long-term target of the mid-70% range, leaving limited room to absorb higher costs.
Selling, general and administrative expenses rose to $297.8 million from $242.8 million a year earlier, mainly due to higher compensation and benefit costs associated with increased sales volume. The company also incurred restructuring expenses as it continues integration and synergy initiatives, which could lead to fluctuations in near-term operating costs.
Globus Medical’s international business adds another source of uncertainty. International net sales reached $155.0 million in the first quarter of 2026, increasing 35.6% year over year on a reported basis and 27.8% on a constant currency basis, highlighting the impact of exchange rate movements on reported results.
The company recorded a $2.1 million foreign currency transaction loss during the quarter, which reduced other income. With significant operations in regions such as Japan, the Eurozone, the United Kingdom and Australia, ongoing currency fluctuations could continue to affect revenue growth, profit margins and operating expenses over time.
Peer Update
Medtronic’s (MDT - Free Report) operations remain vulnerable to cost inflation, reimbursement constraints, geopolitical disruption and changing global trade policies. It also embedded a roughly 1-point EPS drag from higher fuel and transportation costs tied to the recent shift in the geopolitical environment.
Medtronic generates a large portion of sales internationally, leaving reported results sensitive to exchange rates. Foreign exchange added $819 million to fiscal 2026 revenues, but fiscal 2027 guidance assumes a neutral to $100 million revenue drag.
Edwards Lifesciences’ (EW - Free Report) extensive global operations and overseas manufacturing facilities and suppliers bring certain financial, economic, political and other risks. The business is also currently experiencing staffing shortages within the hospital systems.
In the first quarter of 2026, these issues resulted in a 20.2% increase in COGS and a year-over-year decline of 64 basis points in gross margin. Foreign exchange is a major headwind for Edwards due to a considerable percentage of its revenues coming from outside the United States. Foreign exchange rates negatively impacted the second quarter gross profit margin by 60 basis points compared to the prior year.
GMED’s Stock Price Performance
Over the past year, GMED shares have surged 37.1%, outperforming the industry’s 4.6% decline.
Image Source: Zacks Investment Research
GMED’s Valuation
GMED currently trades at a forward 12-month price-to-sales (P/S) of 3.26X compared with the industry median of 4.49X.
Image Source: Zacks Investment Research
GMED Stock Estimate Trend
In the past 30 days, GMED's EPS estimate for 2026 has moved north to $4.74.
Image Source: Zacks Investment Research
GMED currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.